Broncus Holding (HKSE:02216) Total Liabilities: HK$60.33 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02216 Broncus Holding Corp HKSE:02216
43 GF Score
Price HK$0.66
GF Value HK$0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Broncus Holding Total Liabilities?

Broncus Holding HKSE:02216 +1.55% 43 Total Liabilities is HK$60.33 Mil as of Jun. 2026. GuruFocus rates HKSE:02216 with a GF Score™ of 43/100 and a GF Value™ of HK$0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Broncus Holding's Total Liabilities for the quarter that ended in Jun. 2026 was HK$60.33 Mil.

Broncus Holding's quarterly Total Liabilities increased from Jun. 2025 (HK$41.48 Mil) to Dec. 2025 (HK$47.99 Mil) and increased from Dec. 2025 (HK$47.99 Mil) to Jun. 2026 (HK$60.33 Mil).

Broncus Holding's annual Total Liabilities declined from Dec. 2023 (HK$81.50 Mil) to Dec. 2024 (HK$49.89 Mil) and declined from Dec. 2024 (HK$49.89 Mil) to Dec. 2025 (HK$47.99 Mil).

Broncus Holding Total Liabilities Historical Data

* Premium members only.

The historical data trend for Broncus Holding's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Broncus Holding Total Liabilities Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 81.02 66.05 81.50 49.89 47.99

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.33 49.89 41.48 47.99 60.33
HKSE:02216
43GF Score
Broncus Holding Corp HKSE:02216
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Broncus Holding Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Broncus Holding's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=46.07+(0+1.922
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=47.99

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1214.816-1166.824
=47.99

Broncus Holding's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=57.482+(1.16+1.685
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=60.33

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=1180.279-1119.952
=60.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$60.33 Mil mean?
Broncus Holding (HKSE:02216) has a Total Liabilities of HK$60.33 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Broncus Holding and its competitors.
Is Broncus Holding's Total Liabilities too high?
Broncus Holding's current Total Liabilities is HK$60.33 Mil. Overall, Broncus Holding has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's Total Liabilities compare to ABT and SYK?
Broncus Holding's Total Liabilities of HK$60.33 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Broncus Holding and its competitors. Broncus Holding's current Total Liabilities is HK$60.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Based on GuruFocus' analysis, Broncus Holding (HKSE:02216) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.66 — trading 336.7% above its estimated fair value. The current Total Liabilities is HK$60.33 Mil. Broncus Holding's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Broncus Holding (HKSE:02216), the current Total Liabilities is HK$60.33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Broncus Holding (HKSE:02216) Overvalued in 2026?

Based on GuruFocus' analysis, Broncus Holding stock appears to be overvalued. The current stock price of HK$0.66 is trading 336.7% above its estimated GF Value™ of HK$0.15. GuruFocus considers Broncus Holding to be Significantly Overvalued.

Key valuation signals for HKSE:02216:

  • Total Liabilities: HK$60.33 Mil
  • GF Value™: HK$0.15 vs. price of HK$0.66 (336.7% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Broncus Holding Business Description

Address No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
43GF Score

Get the complete analysis for HKSE:02216

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.66
Price
HK$0.15
GF Value